Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Ap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback